Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Graded Insulin Suppression Test (GIST) Pilot & Feasibility Study
NCT06592261Phase 1Completed
- Sponsor
- Columbia University
- Start
- Sep 2024
- Primary completion
- Oct 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of human insulin in insulin resistance (IR), hyperinsulinemia and obesity (3 arms), sponsored by Columbia University. Primary endpoints: Steady-state plasma glucose at euinsulinemia and Steady-state plasma glucose at hyperinsulinemia. Started Sep 2024; status: completed.
02
Drugs
human insulin
03
Conditions
insulin resistance (IR)hyperinsulinemiaobesity
Beyond the preview
Go deeper on NCT06592261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592261.